La cadena de opciones muestra datos clave de las opciones de acciones de CIE Automotive a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CIE Automotive..

CIE Automotive (OTC:CUOTF) Bolsa, Cadena de Opciones

CIE Automotive SA is a supplier of components and subassemblies for the automotive market. Cie Automotive produces components for engines, gearboxes, transmissions, chassis, interior and exterior trims, and roof systems. The company's clients include Renault, Magna, Chrysler, Daimler, Schaeffler, Ford, Nexteer, Volkswagen, and Faurecia. Next to its core automotive business, Cie Automotive operates a process improvement service through a subsidiary. The majority of revenue and operating profits are generated in Cie Automotive's core segment automotive components. Geographically, Europe and NAFTA are the largest sources of operating profits for the company.

CIE AUTOMOTIVE SA ORD by Cie Automotive SA

CIE Automotive SA

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $276,786, and 6 were calls, valued at $363,437.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $200.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $150.0 to $200.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733341561_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.05</td>
<td>$19.6</td>
<td>$19.87</td>
<td>$160.00</td>
<td>$135.1K</td>
<td>2.9K</td>
<td align="right">71</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$24.55</td>
<td>$24.3</td>
<td>$24.55</td>
<td>$160.00</td>
<td>$68.7K</td>
<td>43</td>
<td align="right">28</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.74</td>
<td>$1.63</td>
<td>$1.64</td>
<td>$182.50</td>
<td>$50.6K</td>
<td>716</td>
<td align="right">499</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.6</td>
<td>$9.4</td>
<td>$9.6</td>
<td>$175.00</td>
<td>$48.0K</td>
<td>1.3K</td>
<td align="right">67</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.85</td>
<td>$6.45</td>
<td>$6.42</td>
<td>$150.00</td>
<td>$46.9K</td>
<td>830</td>
<td align="right">299</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,777,110, with ABBV's price down by -2.71%, positioned at $176.59.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 58 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $212.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $206. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on AbbVie with a target price of $208. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $224. 
&#x2A; An analyst from Wolfe Research downgraded its action to Outperform with a price target of $205. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $221. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ABBV

Check Out What Whales Are Doing With ABBV

Investors with a lot of money to spend have taken a bullish stance on Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Dollar Gen.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $690,058, and 7 are calls, for a total amount of $302,829.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $115.0 for Dollar Gen, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Dollar Gen's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Dollar Gen's significant trades, within a strike price range of $55.0 to $115.0, over the past month.
<h3>Dollar Gen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733341556_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$70.00</td>
<td>$162.6K</td>
<td>723</td>
<td align="right">346</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.25</td>
<td>$6.15</td>
<td>$6.25</td>
<td>$75.00</td>
<td>$135.0K</td>
<td>492</td>
<td align="right">255</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$4.5</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$79.00</td>
<td>$86.4K</td>
<td>4.0K</td>
<td align="right">320</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$2.55</td>
<td>$2.54</td>
<td>$2.55</td>
<td>$73.00</td>
<td>$69.6K</td>
<td>15</td>
<td align="right">100</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.75</td>
<td>$9.25</td>
<td>$9.25</td>
<td>$85.00</td>
<td>$67.5K</td>
<td>2.7K</td>
<td align="right">95</td>
</tr>
</tbody>
</table>

<h3>About Dollar Gen</h3>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
Following our analysis of the options activities associated with Dollar Gen, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Dollar Gen</h3>
<ul>
<li>With a volume of 3,691,838, the price of DG is up 0.42% at $79.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Dollar Gen</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $87.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Dollar Gen, maintaining a target price of $80. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Dollar Gen, targeting a price of $82. 
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Dollar Gen, maintaining a target price of $95. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Market Perform rating on Dollar Gen with a target price of $90. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Dollar Gen, maintaining a target price of $90. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Dollar Gen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Dollar Gen Unusual Options Activity For December 04

Whales with a lot of money to spend have taken a noticeably bullish stance on Micron Technology.
Looking at options history for Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 34% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $453,650 and 26, calls, for a total amount of $2,403,146.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $47.5 and $120.0 for Micron Technology, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Micron Technology's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Micron Technology's whale activity within a strike price range from $47.5 to $120.0 in the last 30 days. 
<h3>Micron Technology Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733341551_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$3.75</td>
<td>$3.6</td>
<td>$3.61</td>
<td>$98.00</td>
<td>$1.1M</td>
<td>9.1K</td>
<td>4.0K</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$3.7</td>
<td>$3.65</td>
<td>$3.7</td>
<td>$98.00</td>
<td>$148.7K</td>
<td>9.1K</td>
<td>452</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.0</td>
<td>$9.95</td>
<td>$10.0</td>
<td>$100.00</td>
<td>$137.0K</td>
<td>5.2K</td>
<td>333</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.75</td>
<td>$7.7</td>
<td>$7.75</td>
<td>$100.00</td>
<td>$106.1K</td>
<td>4.5K</td>
<td>179</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$14.25</td>
<td>$14.15</td>
<td>$14.15</td>
<td>$100.00</td>
<td>$70.7K</td>
<td>373</td>
<td>56</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
<h3>Current Position of Micron Technology</h3>
<ul>
<li>Currently trading with a volume of 10,207,538, the MU's price is up by 2.77%, now at $102.61. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Micron Technology options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In Micron Technology Options

WIIM

ALEC

Alector shares are trading lower after the company released its INVOKE-2 Phase 2 trial results that failed to meet its primary endpoint. Also, Bank of America downgraded the stock from Neutral to Underperform.

Despite price consolidation, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) have maintained strong bullish momentum, buoyed by broader market recovery and community enthusiasm.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.4158</td>
<td>$61.1 billion</td>
<td>&nbsp;+2.6%</td>
<td>&nbsp;+3.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00003006</td>
<td>$17.7 billion</td>
<td>&nbsp;+7.2%</td>
<td>&nbsp;+18.7%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00003006</td>
<td>$9 billion</td>
<td>&nbsp;+9%</td>
<td>&nbsp;+8.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Scofield highlighted a bullish chart pattern, saying everything is going as planned:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> Update Going exactly as planned <a href="https://t.co/BnsAIYlRmw">pic.twitter.com/BnsAIYlRmw</a>
&mdash; Scofield (@Crypto_Scofield) <a href="https://twitter.com/Crypto_Scofield/status/1864232980954096019?ref_src=twsrc%5Etfw">December 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Technical analyst Kevin notes that in Dogecoin's previous cycle, after a major rally, the token consolidated for 24 days before surging to a macro golden pocket. 
If history repeats, DOGE's next rally could begin by week's end, with potential targets in the $3.80–$4.00 range.
However, Kevin advises caution, <a href="https://x.com/Kev_Capital_TA/status/1864110830947631236">suggesting</a> a more realistic goal might be a new all-time high by December's end.
Meanwhile, trader Viktor warns of volatility, pointing out that DOGE often dips before significant rallies. He <a href="https://x.com/thedefivillain/status/1864302124596601209">believes</a> the bottom might only come when traders lose confidence
Trader Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1864099025227764217">predicts</a> a retail-driven rally for Shiba Inu, as many investors still hold SHIB from its last cycle. Bluntz sees SHIB as a potential &#8220;easy layup&#8221; for gains.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">bargain basement pricing down here, easy layup imo.<a href="https://twitter.com/search?q=%24shib&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$shib</a> <a href="https://t.co/eAlEXEB0TN">https://t.co/eAlEXEB0TN</a> <a href="https://t.co/s0Ty7kvDDW">pic.twitter.com/s0Ty7kvDDW</a>
&mdash; Bluntz (@Bluntz_Capital) <a href="https://twitter.com/Bluntz_Capital/status/1864101191170576861?ref_src=twsrc%5Etfw">December 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On the other hand, Milk Road platform <a href="https://x.com/MilkRoadDaily/status/1864327570793353641">reported</a> a $1.5 million transfer of SHIB by the U.S. government, adding intrigue to recent market dynamics.
Statistics: IntoTheBlock data shows Dogecoin large transaction volume increasing by 41.1%, while Shiba Inu saw a 52% drop in large transaction volume. &nbsp;DOGE daily active addresses grew by 34.9% and SHIB saw a 17.8% drop. 
SHIB transactions greater than $100,000 are down from 892 to 685 in a single day. Currently, 69% SHIB holders are making profit.  In the month of November, 3.16 billion SHIB coins have been <a href="https://x.com/shibburn/status/1863087923626737769">burned</a> through 167 transactions.
What's Next: The ongoing rallies for Dogecoin and Shiba Inu reflect a mix of technical patterns, retail enthusiasm and institutional interest. However, traders are cautious about predicting exact timelines <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">for future gains</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42228849/dogs-cats-and-frogs-cryptos-wildest-winners-in-2024-the-unexpected-tokens-turning-pocket-change-into-fortunes">Dogs, Cats And Frogs — Crypto&#8217;s Wildest Winners In 2024: The Unexpected Tokens Turning Pocket Change Into Fortunes</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$DOGE

$PEPE

$SHIB

DOGE Up 3%, SHIB Up 7%: How High Can Dogecoin, Shiba Inu Go?

Burning Rock Biotech shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Federal Reserve Chair Jerome Powell painted a rosy picture of the U.S. economy ahead of key jobs data due Friday. The strength of the economy is allowing the Fed to be <a href="https://www.benzinga.com/news/econ-s/24/12/42316647/interest-rate-cut-in-december-st-louis-feds-musalem-urges-patient-approach-in-last-mile-to-2">more cautious with interest rates</a>.
What Happened: Speaking at the New York Times DealBook Summit on Wednesday, Powell stressed that the current state of the economy allows the Fed to exercise caution in moving rates back down to a more neutral level.
&#8220;The U.S. economy is in very good shape right now. It&#8217;s in remarkably good shape, we are sort of the envy of other large economies around the world, and I&#8217;m going to do everything I can to keep it there during the rest of my term, and I feel very good about where the economy is and where monetary policy is,&#8221; Powell said.
The economy is growing at about a 2.5% clip and inflation has come down from above 7% to around 2.3%, while unemployment remains in check, the Fed chair said.
&#8220;We&#8217;re not quite there on inflation, but we&#8217;re still making progress &#8230; We&#8217;re now on a path to bring rates back down to a more neutral level over time,&#8221; Powell said.
&#8220;The good news is that we can afford to be a little more cautious as we try to find neutral.&#8221;
If the Fed lowers rates too quickly, it risks undermining the progress the central bank has made on inflation, but if it moves toward neutral too slowly, it could cause unnecessary harm to the labor market.
Check This Out: <a href="https://www.benzinga.com/news/econ-s/24/12/42316647/interest-rate-cut-in-december-st-louis-feds-musalem-urges-patient-approach-in-last-mile-to-2">Interest Rate Cut In December? St. Louis Fed&#8217;s Musalem Urges &#8216;Patient Approach&#8217; In &#8216;Last Mile&#8217; To 2%</a>
Why It Matters: The Fed lowered interest rates <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">by 0.25% in November</a>, bringing the federal funds target range to between 4.5% and 4.75%, marking the lowest levels seen since February 2023.
The Fed is currently in a &#8220;quiet&#8221; period ahead of its next interest rate decision, due on Dec. 18. The implied probability of a 0.25% rate cut at the Fed&#8217;s next meeting currently sits at 75.5%, according to CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>. Another cut to rates later this month would mark the Fed&#8217;s third consecutive interest rate cut.
Powell <a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates">said in mid-November</a> that the Fed was in a position to &#8220;carefully&#8221; consider the appropriate level of rate cuts and did not need to &#8220;hurry,&#8221; pushing the odds for another cut in December lower. However, the implied probability moved higher earlier this week after Fed Governor Christopher Waller said he was <a href="https://www.benzinga.com/news/24/12/42282037/federal-reserves-waller-leans-toward-rate-cut-in-december-cites-inflations-downward-path-to-2">&#8220;leaning toward&#8221;</a> a rate cut later this month.
The Fed will get another look at key jobs data on Friday when the Bureau of Labor Statistics reports unemployment figures for November at 8:30 a.m. ET.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42318715/us-services-sector-growth-cools-more-than-expected-in-november-as-businesses-show-cautionary-outlooks-on-tariffs">US Services Sector Growth Cools More Than Expected In November As Businesses Show &#8216;Cautionary Outlooks&#8217; On Tariffs</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Fed Chair Powell speaks at the New York Times DealBook Summit 2024" width="500" height="281" src="https://www.youtube.com/embed/4umAoF9l17c?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Image created using artificial intelligence via Midjourney.

Econ #s

Federal Reserve

Jerome Powell Says US Economy In 'Remarkably Good Shape,' Fed Can Be 'A Little More Cautious' With Interest Rates

Macro Notification

General

French Government Falls As National Assembly Approves No-Confidence Vote

RBC Capital Markets analyst Rishi Jaluria reiterated an Underperform rating and a price target of $21 on Box Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) <a href="https://www.benzinga.com/quote/BOX/analyst-ratings" target="_blank" rel="noreferrer noopener">after the third-quarter results</a>.
On Tuesday, Box reported earnings of 45 cents per share, which beat the analyst consensus estimate of 42 cents, and revenue of $276 million, which beat the <a href="https://www.benzinga.com/news/earnings/24/12/42303665/box-stock-dips-after-narrow-q3-eps-revenue-beats-details" target="_blank" rel="noreferrer noopener">consensus estimate of $275.17 million</a>.
Box sees fourth-quarter revenue of $279 million versus the $278.544 million estimate, and adjusted earnings of 41 cents per share,<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener"> in line with estimates</a>.
The analyst says the quarter was mixed, and until further clarity on customer interest in Enterprise Advanced emerges, the company&#8217;s thesis remains unchanged.
Positively, management noted further signs of easing macro headwinds, added the analyst.
The analyst wrote that he is encouraged by the expected 20%-40% pricing uplift for customers upgrading to the new Enterprise Advanced plan, set to launch in January. But widespread enterprise adoption, critical for significant pricing gains, may face delays amid ongoing privacy concerns, noted the analyst.
As a result, Jaluria said he finds it challenging to forecast FY26 acceleration, reinforcing the view that long-term targets remain a best-case scenario.
The analyst said FY25 revenue guidance was raised by $2 million on an as-reported basis, which reflected a net $3 million increase in constant currency after FX changes were factored in.
Despite a lack of significant upside in the third quarter, the guidance increase was encouraging, similar to the second quarter, and suggested improved visibility into the company&#8217;s results.
Investors can gain exposure to the stock via Global X Cloud Computing ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOU#NASDAQ">CLOU</a>) and Invesco S&amp;P SmallCap Information Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCT#NASDAQ">PSCT</a>).
BOX Price Action: BOX shares are down 7.61% at $31.80 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41796344/tim-cook-mark-zuckerberg-and-jeff-bezos-congratulate-trump-whats-next-for-the-tech-giants" target="_blank" rel="noreferrer noopener">Tim Cook, Mark Zuckerberg, And Jeff Bezos Congratulate Trump: What&#8217;s Next For The Tech Giants?</a></li>
</ul>
Photo: Shutterstock

Equities

Mid Cap

Movers

CLOU

PSCT

Box Posts Earnings Beat, But Analyst Maintains Bearish View About Uncertain Enterprise Advanced Adoption

Globe Life Refutes Viceroy Research's Short Seller Allegations, Highlights Growth To 12K Agents And 17M Policies, Accusing Report Of Misrepresentation And Misleading Claims To Damage Reputation And Stock Price

Investors with a lot of money to spend have taken a bullish stance on Nano Nuclear Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NNE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Nano Nuclear Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $37,000, and 9, calls, for a total amount of $717,649.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $35.0 for Nano Nuclear Energy during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Nano Nuclear Energy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Nano Nuclear Energy's substantial trades, within a strike price spectrum from $25.0 to $35.0 over the preceding 30 days.
<h3>Nano Nuclear Energy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733340713_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.4</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$25.00</td>
<td>$202.6K</td>
<td>1.8K</td>
<td>2.1K</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.8</td>
<td>$6.3</td>
<td>$6.6</td>
<td>$25.00</td>
<td>$198.0K</td>
<td>1.0K</td>
<td>523</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.6</td>
<td>$6.3</td>
<td>$6.6</td>
<td>$25.00</td>
<td>$66.0K</td>
<td>1.0K</td>
<td>219</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.6</td>
<td>$6.3</td>
<td>$6.6</td>
<td>$25.00</td>
<td>$66.0K</td>
<td>1.0K</td>
<td>119</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$25.00</td>
<td>$55.0K</td>
<td>27</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About Nano Nuclear Energy</h3>
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
After a thorough review of the options trading surrounding Nano Nuclear Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Nano Nuclear Energy</h3>
<ul>
<li>With a trading volume of 6,156,946, the price of NNE is down by -1.22%, reaching $26.3.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>Expert Opinions on Nano Nuclear Energy</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $58.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $50. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Nano Nuclear Energy, which currently sits at a price target of $66. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Nano Nuclear Energy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on Nano Nuclear Energy: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on MARA Holdings.
Looking at options history for MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) we detected 39 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 48% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $506,705 and 30, calls, for a total amount of $3,242,596.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $50.0 for MARA Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for MARA Holdings options trades today is 7765.15 with a total volume of 36,427.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for MARA Holdings's big money trades within a strike price range of $5.0 to $50.0 over the last 30 days.
<h3>MARA Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733340708_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$12.45</td>
<td>$11.65</td>
<td>$11.95</td>
<td>$37.00</td>
<td>$1.4M</td>
<td>4.1K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$11.15</td>
<td>$10.1</td>
<td>$10.33</td>
<td>$30.00</td>
<td>$309.9K</td>
<td>5.4K</td>
<td>602</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.3</td>
<td>$7.41</td>
<td>$50.00</td>
<td>$222.3K</td>
<td>14.4K</td>
<td>958</td>
</tr>
<tr>
<td>MARA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.63</td>
<td>$29.50</td>
<td>$104.1K</td>
<td>1.6K</td>
<td>250</td>
</tr>
<tr>
<td>MARA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$4.25</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$29.00</td>
<td>$94.5K</td>
<td>2.7K</td>
<td>497</td>
</tr>
</tbody>
</table>

<h3>About MARA Holdings</h3>
MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value.
Following our analysis of the options activities associated with MARA Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is MARA Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 46,724,785, the price of MARA is up by 0.86%, reaching $25.34.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 84 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for MARA Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MARA

MARA Holdings Unusual Options Activity For December 04

Deep-pocketed investors have adopted a bullish approach towards Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SHOP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 36 extraordinary options activities for Shopify. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $296,377, and 31 are calls, amounting to $1,900,164.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $160.0 for Shopify over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Shopify's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale trades within a strike price range from $45.0 to $160.0 in the last 30 days. 
<h3>Shopify Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733340702_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.25</td>
<td>$29.5</td>
<td>$29.76</td>
<td>$105.00</td>
<td>$297.6K</td>
<td>3.8K</td>
<td align="right">103</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.8</td>
<td>$27.0</td>
<td>$27.6</td>
<td>$110.00</td>
<td>$276.0K</td>
<td>2.3K</td>
<td align="right">149</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$36.7</td>
<td>$34.1</td>
<td>$35.1</td>
<td>$95.00</td>
<td>$105.3K</td>
<td>7.1K</td>
<td align="right">35</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$37.35</td>
<td>$37.15</td>
<td>$37.21</td>
<td>$80.00</td>
<td>$100.4K</td>
<td>1.5K</td>
<td align="right">28</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$48.4</td>
<td>$48.15</td>
<td>$48.4</td>
<td>$70.00</td>
<td>$96.8K</td>
<td>7.3K</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Shopify</h3>
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
Having examined the options trading patterns of Shopify, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Shopify Standing Right Now?</h3>
<ul>
<li>With a volume of 5,192,439, the price of SHOP is up 0.83% at $112.79. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Professional Analyst Ratings for Shopify</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $118.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Shopify, which currently sits at a price target of $120. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Shopify with a target price of $130. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Shopify, which currently sits at a price target of $130. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Shopify with a target price of $94. 
&#x2A; An analyst from JMP Securities persists with their Market Outperform rating on Shopify, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Shopify with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SHOP

Shopify Options Trading: A Deep Dive into Market Sentiment

The Biden-Harris administration has announced an initiative to improve access to gene therapies for <a href="https://www.benzinga.com/topic/sickle-cell-disease">sickle cell disease</a> under the Cell and Gene Therapy Access Model.
This voluntary model, developed by the Center for Medicare and Medicaid Innovation, seeks to enhance access to these therapies, improve patient outcomes, and reduce healthcare costs by tying payments to treatment efficacy for Medicaid recipients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42243241/fda-probes-potential-life-threatening-blood-cancer-risks-linked-to-bluebird-bios-skysona-gene-therapy" rel="noreferrer noopener">FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio&#8217;s Skysona Gene Therapy</a>
Two drug manufacturers, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), have agreed to participate in the model with their FDA-approved therapies, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016766/jp-morgan-downgrades-gene-therapy-focused-bluebird-bio-cites-limited-funding-options" rel="noreferrer noopener">Lyfgenia</a> and <a target="_blank" href="https://www.benzinga.com/news/24/01/36657324/gene-therapy-for-beta-thalassemia-crispr-therapeuticsvertexs-casgevy-secures-fda-nod-ahead-of-schedu" rel="noreferrer noopener">Casgevy</a>.
CMS is working to <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-steps-increase-access-sickle-cell-disease-treatments" rel="noreferrer noopener">engage</a> states and U.S. territories enrolled in the Medicaid Drug Rebate Program, providing technical support and data infrastructure for implementation.
States may apply to participate starting this month, with applications accepted until Feb. 28, 2025.
Over 100,000 individuals in the U.S. live with sickle cell disease, more than half of whom rely on Medicaid. The disease significantly reduces life expectancy and imposes an annual economic burden of nearly $3 billion in healthcare costs.
The Food and Drug Administration (FDA) approved Lyfgenia and Casgevy in December 2023 as gene therapies targeting <a href="https://www.benzinga.com/general/biotech/23/12/36156713/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder" target="_blank" rel="noreferrer noopener">sickle cell disease</a>.
Launching in January 2025, the model allows states to join until January 2026. States can also apply for optional funding to support implementation.
This initiative aligns with President Biden's 2022 Executive Order to expand access to novel therapies and reduce prescription drug costs. Future expansions of the model may include other cell and gene therapies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42321484/fords-mustang-mach-e-sales-skyrocket-383-in-november-amid-growing-ev-momentum" target="_blank" rel="noreferrer noopener">Ford&#8217;s Mustang Mach-E Sales Skyrocket 38.3% In November Amid Growing EV Momentum</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

BLUE

VRTX

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program

SGBX

Safe & Green shares are trading higher after the company announced it signed two contracts for modular construction projects.

Hershey shares are trading higher amid unconfirmed rumors suggesting the company is in talks to be acquired.

Bluebird Bio shares are trading higher after the company announced it joined the CMMI cell and gene therapy access model and will offer outcomes-based agreements to expand Medicaid access to LYFGENIA gene therapy for sickle cell disease.

In November, Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) reported <a href="https://www.benzinga.com/news/earnings/24/11/41791722/applovin-stock-soars-after-q3-earnings-report-revenue-beat-eps-beat-strong-software-platform-growth" target="_blank" rel="noreferrer noopener">third-quarter revenue</a> of $1.20 billion, up 39%, topping the analyst consensus estimate of $1.13 billion. EPS of $1.25 beat the analyst consensus estimate of $0.94.
Despite the strong results, Goldman Sachs analyst Eric Sheridan maintained a Neutral rating on the stock, with a price target of $220.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution" rel="noreferrer noopener">AppLovin&#8217;s High Valuation and Expansion Beyond Gaming Prompt Analyst Caution</a>
Applovin&#8217;s board raised the company&#8217;s share buyback program by $2 billion.&nbsp;
The company expects fourth-quarter revenue of $1.24 billion—$1.26 billion compared to the consensus of $1.25 billion.&nbsp;
Sheridan&#8217;s rating reflects his view that the stock from current levels is potentially volatile on short- and medium-term results. It presents a more balanced risk and reward in a multi-year timeframe.
Sheridan recapitulated his recently hosted investor meeting with AppLovin chief Adam Foroughi, CFO Matt Stumpf, and Head of IR David Hsiao. The analyst flagged the evolution of AXON 2.0 to drive continued growth, strong operating margins, a capital-light model, and longer-term upside optionality by applying generative AI to a creative and faster cadence of developer enhancements.
Like the trends and themes from their third-quarter 2024 earnings call, management highlighted how AXON 2.0 continues to evolve as a neural net and AI platform that can improve the efficiency of its current advertising business. In addition, it demonstrated some early success around the eCommerce opportunity. The last point also aligns with some of the analyst&#8217;s early fourth-quarter advertising industry channel checks.
Despite the management team&#8217;s success in terms of revenue growth (as reflected in its market cap &#8211; shares are up 856% year-to-date), the company continues to emphasize a focus on driving operational execution in a relatively asset-light model while maintaining company culture, cost efficiencies, and returning capital to shareholders.  
While management expressed optimism about the multi-year market opportunity ahead, the key investor debate will likely remain focused on the linearity of the path forward in terms of sequential and year-on-year revenue trajectory as the platform scales, Sheridan said.
Putting aside any such quarterly short-term debates, Sheridan noted that AppLovin was positively exposed to the broader secular growth themes in advertising of AI and machine learning, increased ad budgets, and campaign efficiency.
In the coming quarters, investors are likely to continue to examine operating results for outcomes around the emerging revenue streams (into 2025 and 2026), especially regarding the ramp of the broader commerce opportunity.
On the operating fundamentals, Sheridan remained constructive that AppLovin has a collection of businesses that can produce above-average advertising and marketing industry growth (Sheridan&#8217;s fiscal 2024-2027 revenue CAGR is ~19%) and a strong margin profile in normalized mobile ads and mobile gaming landscape.
Sheridan projected fiscal 2024 revenue of $4.59 billion and EPS of $4.02.
Price Action: APP stock is up 1.3% at $371.32 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42321266/meta-joins-big-techs-shift-to-nuclear-power-for-ai-ambitions" target="_blank" rel="noreferrer noopener">Meta Joins Big Tech&#8217;s Shift To Nuclear Power For AI Ambitions</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

Applovin Set To Capitalize On AI Frenzy, Ad Growth, Analyst Cautions On Near-Term Volatility

Bank of America Securities has downgraded Alector, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>), citing the failure <a href="https://www.benzinga.com/topic/alzheimers-disease">of its AL002 program</a>. 
Alector recently released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with <a href="https://www.benzinga.com/24/11/42192908/alectorabbvie-partnered-alzheimers-drug-disappoints-in-mid-stage-study-lays-off-17-of-workforce" target="_blank" rel="noreferrer noopener">early Alzheimer&#8217;s disease (AD)</a>.
But AL002 failed to meet the primary endpoint of slowing Alzheimer&#8217;s clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB).
The analyst writes, &#8220;We see this as likely the end for the AL002 program, and combined with the 17% workforce reduction, we do not expect the $250M opt-in milestone from AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) to be realized.&#8221;
The AL002 results are expected to impact sentiment as investors wait for Phase 3 data on latozinemab for frontotemporal dementia&nbsp;(FTD).
INFRONT-3 Phase 3 trial completed enrollment in October 2023 and a treatment <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786512/alector-reports-third-quarter-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">duration of 96 weeks</a>.
The lack of near-term clinical milestones adds further pressure.
The analyst has downgraded from Neutral to Underperform and reduced the price target to <a target="_blank" href="https://www.benzinga.com/quote/ALEC/analyst-ratings" rel="noreferrer noopener">$1 (previously $9)</a>, reflecting the removal of AL002, lower valuation for AL001, and the significant investment required for future pipeline growth.
BofA anticipates that Alector&#8217;s next big milestone will be the Phase 3 INFRONT-3 trial results, which are expected in late 2025 or early 2026.
While the analyst remains optimistic about AL001 and its approach of targeting progranulin (compared to AL002, which focuses on TREM2), the novel pathway for treating FTD carries a similar level of biological risk.
AL101 offers another potential avenue for Alzheimer&#8217;s disease, but BofA is cautious about its prospects until it demonstrates functional benefits, which are key to its success.
Over the next year, the analyst views Alector as being in a &#8220;wait-and-see&#8221; phase, with limited opportunities for significant progress in the near term.
Price Action: Alector stock is down 10.7% at $2.25 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42321510/mastercard-settles-uk-antitrust-lawsuit-for-250-million" target="_blank" rel="noreferrer noopener">Mastercard Settles UK Antitrust Lawsuit For $250 Million</a></li>
</ul>
Image: Shutterstock

Comments

CIE Automotive

CIE Automotive (CUOTF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL